Stubborn Valeant powers ahead with extended Allergan buyout offer

Valeant's ($VRX) tender offer for Allergan ($AGN) isn't expiring just yet. The company has extended the deadline to Dec. 31, giving it and activist investor partner Bill Ackman a few more months to go after deal-averse Allergan. At least one supporter is betting heavily that the Canadian pharma can pull the deal off: Paulson & Co. acquired 5.6 million shares of Allergan valued at nearly $1 billion during the second quarter, Bloomberg reports. News (sub. req.) | More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.